In Vivo Model Systems in P-Glycoprotein-Mediated Multidrug Resistance

References

• Chin K-V, Pastan I Gottesman MM. Function and regulation of the human multi-drug resistance gene. Adv Cancer Res 1993; 60: 157–80.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385–427.
   PubMed Web of Science ®Google Scholar
• Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv Clin Chem 1994; 31: 1–61.
   PubMed Web of Science ®Google Scholar
• van der Heyden S, Gheuens E, De Bruijn E, et al. P-glycoprotein: clinical significance and methods of analysis. Crit Rev Clin Lab Sci 1995; 32: 221–64.
   PubMed Web of Science ®Google Scholar
• Broxterman HJ, Lankelma J Pinedo HM. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer 1996; 32A: 1024–33.
   Google Scholar
• Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations. Cancer Res 1996; 56: 3010–20.
   PubMed Web of Science ®Google Scholar
• Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265–9.
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116–24.
   PubMed Web of Science ®Google Scholar
• Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160–4.
   PubMed Web of Science ®Google Scholar
• Ro J, Sahin A, Ro JY, et al. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990; 21: 787–91.
   PubMed Web of Science ®Google Scholar
• Bourhis J, Goldstein LJ, Riou G, et al. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res 1989; 49: 5062–5.
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, Fojo AT, Ueda K, et al. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J Clin Oncol 1990; 8: 128–36.
   Google Scholar
• Chan HSL, DeBoer G, Haddad G, et al. Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am 1995; 9: 275–318.
   PubMed Web of Science ®Google Scholar
• Goldstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer 1996; 32A: 1039–50.
   PubMed Web of Science ®Google Scholar
• Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708–12.
   PubMed Web of Science ®Google Scholar
• Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–6.
   PubMed Web of Science ®Google Scholar
• Sato H, Gottesman MM, Goldstein LJ, et al. Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Res 1990; 14: 11–22.
   PubMed Web of Science ®Google Scholar
• Miller TP, Grogan TM, Dalton WS, et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9: 17–24.
   PubMed Web of Science ®Google Scholar
• Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490–5.
   PubMed Web of Science ®Google Scholar
• Licht T, Pastan I, Gottesman M, et al. P-Glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol 1994; 69: 159–71.
   PubMed Web of Science ®Google Scholar
• Nooter K, Sonneveld P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leukemia Res 1994; 18: 233–43.
   PubMed Web of Science ®Google Scholar
• Chan HSL, Thorner PS, Haddad G, et al. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689–704.
   PubMed Web of Science ®Google Scholar
• Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325: 1608–14.
   PubMed Web of Science ®Google Scholar
• Zhou DC, Marie JP, Suberville AM, et al. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879–85.
   PubMed Web of Science ®Google Scholar
• Holmes JA, West RR. The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia. Br J Cancer 1994; 69: 382–4.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381–9.
   PubMed Web of Science ®Google Scholar
• Juranka PF, Zastawny RL Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989; 3: 2583–92.
   PubMed Web of Science ®Google Scholar
• Croop JM. P-glycoprotein structure and evolutionary homologies. Cytotechnol-ogy 1993; 12: 1–32.
   Google Scholar
• Buschman E, Lepage P Gros P. P-glycoprotein homologues. Cancer Treat Res 1994; 73: 17–39.
   Google Scholar
• Shen D-w, Fojo A, Roninson IB, et al. Multidrug resistance in DNA-mediated transformants is linked to transfer of the human mdr1 gene. Mol Cell Biol 1986; 6: 4039–45.
   PubMed Web of Science ®Google Scholar
• Ueda K, Cardarelli C, Gottesman MM, et al. Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004–8.
   PubMed Web of Science ®Google Scholar
• Van der Bliek AM, Kooiman PM, Schneider C, et al. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 1988; 71: 401–11.
   PubMed Web of Science ®Google Scholar
• Gros P, Croop J Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986; 47: 371–80.
   PubMed Web of Science ®Google Scholar
• Gros P, Raymond M, Bell J, et al. Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 1988; 8: 2770–8.
   PubMed Web of Science ®Google Scholar
• Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Moll Cell Biol 1990; 10: 1652–63.
   PubMed Web of Science ®Google Scholar
• Deuchars KL, Duthie M Ling V. Identification of distinct P-glycoprotein gene sequences in rat. Biochim Biophys Acta 1992; 1130: 157–65.
   Google Scholar
• Endicott JA, Sarangi F Ling V. Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family. DNA Seq 1991; 2: 89–101.
   PubMedGoogle Scholar
• Childs S, Ling V. Duplication and evolution of the P-glycoprotein genes in pig. Biochim Biophys Acta 1996; 1307: 205–12.
   PubMed Web of Science ®Google Scholar
• Silverman JA, Raunio H, Gant TW, et al. Cloning and characterization of a member of the rat multidrug resistance (mdr) gene family. Gene 1991; 106: 229–36.
   PubMed Web of Science ®Google Scholar
• Smit JJM, Schinkel AH, Mol CAAM, et al. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest 1994; 71: 638–49.
   PubMedGoogle Scholar
• Ng WF, Sarangi F, Zastawny RL, et al. Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 1989; 9: 1224–32.
   PubMed Web of Science ®Google Scholar
• Hsu SI-H, Lothstein L Horwitz SB. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. J Biol Chem 1989; 264: 12053–62.
   PubMed Web of Science ®Google Scholar
• Devine SE, Hussain A, Davide JP, et al. Full-length and alternatively spliced pgp1 transcripts in multidrug-resistant Chinese hamster lung cells. J Biol Chem 1991; 266: 4545–55.
   Google Scholar
• Arceci RJ, Croop JM, Horwitz SB, et al. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988; 85: 4350–4.
   PubMed Web of Science ®Google Scholar
• Croop JM, Raymond M, Haber D, et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989; 9: 1346–50.
   PubMed Web of Science ®Google Scholar
• Teeter LD, Becker FF, Chisari FV, et al. Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 1990; 10: 5728–35.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Mol CAAM, Wagenaar E, et al. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995; 31A: 1295–8.
   PubMed Web of Science ®Google Scholar
• Baas F, Borst P. The tissue dependent expression of hamster P-glycoprotein genes. FEBS Lett 1988; 229: 329–32.
   PubMed Web of Science ®Google Scholar
• Bradley G, Georges E, Ling V. Sex-dependent and independent expression of the P-glycoprotein isoforms in Chinese hamster. J Cell Physiol 1990; 145: 398–408.
   PubMed Web of Science ®Google Scholar
• Chin JE, Soffir R, Noonan KE, et al. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989; 9: 3808–20.
   PubMed Web of Science ®Google Scholar
• Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype. Blood 1992; 80: 2729–34.
   PubMed Web of Science ®Google Scholar
• Brown PC, Thorgeirsson SS Silverman JA. Cloning and regulation of the rat mdr2 gene. Nucl Acids Res 1993; 21: 3885–91.
   Google Scholar
• Furuya KN, Gebhart R, Schuetz EG, et al. Isolation of rat pgp3 cDNA: evidence for gender and zonal regulation of expression in the liver. Biochim Biophys Acta 1994; 1219: 636–44.
   Google Scholar
• Buschman E, Arceci RJ, Croop JM, et al. mdr2 Encodes P-glycoprotein expressed in the bile canalicular membrane as determined by isoform-specific antibodies. J Biol Chem 1992; 267: 18093–9.
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735–8.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O’Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277–87.
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159–64.
   PubMed Web of Science ®Google Scholar
• Georges E, Bradley G, Gariepy J, et al. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 1990; 87: 152–6.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O’Brien JP, Casals D, et al. Mulidrug-resistance gene (P-gly-coprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695–8.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491–502.
   PubMed Web of Science ®Google Scholar
• Chin KV, Chauhan SS, Pastan I, et al. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1990; 1: 361–5.
   PubMedGoogle Scholar
• Teeter LD, Estes M, Chan JV, et al. Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol Carcinog 1993; 8: 67–73.
   PubMed Web of Science ®Google Scholar
• Hill BA, Brown PC, Preisegger K-H, et al. Regulation of mdr1b gene expression in Fischer, Wistar and Sprague-Dawley rats in vivo and in vitro. <i>Carcinogenesis1996; 17: 451–7.
   Google Scholar
• Jetté L, Beaulieu E, Leclerc J-M, et al. Cyclosporin A treatment induces over-expression of P-glycoprotein in the kidney and other tissues. Am J Physiol 1996; 270: F756–65.
   PubMed Web of Science ®Google Scholar
• Borst P, Schinkel AH, Smit JJM, et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993; 60: 289–99.
   PubMed Web of Science ®Google Scholar
• Dutt A, Heath LA, Nelson JA. P-glycoprotein and organic cation secretion by the mammalian kidney. J Pharmacol Exp Ther 1994; 269: 1254–60.
   PubMed Web of Science ®Google Scholar
• Speeg KV, Maldonado AL, Liaci J, et al. Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo. J Pharmacol Exp Ther 1992; 261: 50–5.
   PubMed Web of Science ®Google Scholar
• Speeg KV, Maldonado AL. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchinine and doxorubincin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol 1994; 34: 133–6.
   PubMed Web of Science ®Google Scholar
• De Lannoy IAM, Mandin RS Silverman M. Renal secretion of vinblastine, vin-cristine and colchicine in vivo. J Pharmacol Exp Ther 1994; 268: 388–95.
   Google Scholar
• Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the multidrug-resis-tance gene product, in the brush border of rat intestinal mucosa. Gastroenterol-ogy 1992; 102: 879–85.
   PubMed Web of Science ®Google Scholar
• Saitoh H, Aungst BJ. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharmacol Res 1995; 12: 1304–10.
   Google Scholar
• Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharma-cokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94: 4028–33.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031–5.
   PubMed Web of Science ®Google Scholar
• Kamimoto Y, Gatmaitan Z, Hsu J, et al. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem 1989; 264: 11693–8.
   PubMed Web of Science ®Google Scholar
• Schrenk D, Gant TW, Preisegger K-H, et al. Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology 1993; 17: 854–60.
   PubMed Web of Science ®Google Scholar
• Speeg KV, Maldonado AL. Effect of cyclosporine on colchincine partitioning in the rat liver. Cancer Chemother Pharmacol 1993; 32: 434–6.
   Google Scholar
• Tatsuta T, Naito M, Oh-hara T, et al. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992; 267: 20383–91.
   PubMed Web of Science ®Google Scholar
• Barrand MA, Robertson KJ von Weikersthal SF. Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothe-lial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett 1995; 374: 179–83.
   PubMed Web of Science ®Google Scholar
• Didier AD, Loor F. Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int J Cancer 1995; 63: 263–7.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang H, Miller DW, et al. Effect of the P-glycoprotein inhibitor, cyclo-sporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun 1995; 211: 719–26.
   PubMed Web of Science ®Google Scholar
• Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992; 267: 24248–52.
   PubMed Web of Science ®Google Scholar
• van Kalken CK, Broxterman HJ, Pinedo HM, et al. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 1993; 67: 284–9.
   PubMed Web of Science ®Google Scholar
• Yang C-PH, Cohen D, Greenberger LM, et al. Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem 1990; 265: 10282–8.
   PubMed Web of Science ®Google Scholar
• Arceci RJ, Baas F, Raponi R, et al. Multidrug resistance gene expression is controlled by steroid hormones in the secretory epithelium of the uterus. Mol Reprod Dev 1990; 25: 101–9.
   PubMed Web of Science ®Google Scholar
• Chin KV, Chauhan SS, Abraham I, et al. Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines. J Cell Physiol 1992; 152: 87–94.
   Google Scholar
• Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdr1a P-gly-coprotein in mice affects tissue distribution and pharmacokinetics of dexametha-sone, digoxin, and cyclosporin A. J Clin Invest 1995; 96: 1698–705.
   PubMed Web of Science ®Google Scholar
• Valverde MA, Bond TD, Hardy SP, et al. The multidrug resistance P-glycopro-tein modulates cell regulatory volume decrease. EMBO J 1996; 15: 4460–8.
   PubMed Web of Science ®Google Scholar
• De Greef C, van der Heyden S, Viana F, et al. Lack of correlation between mdr-1 expression and volume-activation of chloride-currents in rat colon cancer cells. Pflugers Arch 1995; 430: 296–8.
   Google Scholar
• Schinkel AH, Roelofs MEM Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991; 51: 2628–35.
   PubMed Web of Science ®Google Scholar
• Smit JJM, Schinkel AH, Oude Elferink RPJ, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451–62.
   PubMed Web of Science ®Google Scholar
• Borst P, Schinkel AH. What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer 1996; 32A: 985–90.
   PubMed Web of Science ®Google Scholar
• Oude Elferink RPJ, Groen AK. The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. J Hepatol 1995; 23: 617–25.
   Google Scholar
• Gros P, Ben Neriah YB, Croop JM, et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986; 323: 728–31.
   PubMed Web of Science ®Google Scholar
• Raymond M, Rose E, Housman DE, et al. Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells. Mol Cell Biol 1990; 10: 1642–51.
   PubMed Web of Science ®Google Scholar
• Schott B, Bennis S, Pourquier P, et al. Differential over-expression of mdr1 genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vin-cristine. Int J Cancer 1993; 55: 115–21.
   PubMed Web of Science ®Google Scholar
• Barrand MA, Twentyman PR. Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies. Br J Cancer 1992; 65: 239–45.
   Google Scholar
• Lothstein L, Hsu SI-H, Horwitz SB, et al. Alternate overexpression of two phosphoglycoprotein genes is associated with changes in multidrug resistance in a J774.2 cell line. J Biol Chem 1989; 264: 16054–8.
   PubMed Web of Science ®Google Scholar
• Ganapathi R, Kuo T, Teeter L, et al. Relationship between expression of P-glyco-protein and efficacy of trifluoperazine in multidrug-resistant cells. Mol Pharmacol 1991; 39: 1–8.
   Google Scholar
• Kajiji S, Talbot F, Grizzuti K, et al. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. Biochemistry 1993; 32: 4185–94.
   PubMedGoogle Scholar
• Tang-Wai DF, Kajiji S, DiCapua F, et al. Human (MDR1) and mouse (mdr1,mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995; 34: 32–9.
   PubMed Web of Science ®Google Scholar
• Kajiji S, Dreslin JA, Grizzuti K, et al. Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at Serine939/941. Biochemistry 1994; 33: 5041–8.
   Google Scholar
• Devine SE, Melera PW. Diversity of multidrug resistance in mammalian cells. J Biol Chem 1994; 269: 6133–9.
   Google Scholar
• Shen D-w, Cardarelli C, Hwang J et al. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamy-cin, or vinblastine show changes in expression of specific proteins. J Biol Chem 1986; 261: 7762–70.
   PubMed Web of Science ®Google Scholar
• Choi K, Chen C-j, Kriegler M, et al. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1988; 53: 519–29.
   PubMed Web of Science ®Google Scholar
• Gros P, Dhir R, Croop J, et al. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc Natl Acad Sci USA 1991; 88: 7289–93.
   PubMed Web of Science ®Google Scholar
• Foote SJ, Kyle DE, Martin RK, et al. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 1990; 345: 255–8.
   PubMed Web of Science ®Google Scholar
• Cardarelli CO, Aksentijevich I, Pastan I, et al. Differential effects of P-glycopro-tein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 1995; 55: 1086–91.
   Google Scholar
• Moore AS, Leveille CR, Reimann KA, et al. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995; 13: 475–9.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Hughes CS, Fine RL, et al. P-glycoprotein expression in canine lympho-ma. A relevant, intermediate model of multidrug resistance. Cancer 1996; 77: 1892–8.
   PubMed Web of Science ®Google Scholar
• Keith WN, Mee PJ Brown R. Response of mouse skin tumors to doxorubicin is dependent on carcinogen exposure. Cancer Res 1990; 50: 6841–7.
   Google Scholar
• Spoelstra EC, Dekker H, Schuurhuis GJ, et al. P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. Biochem Pharmacol 1991; 41: 349–59.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Tsuge H, Oh-Hara T, et al. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 1995; 34: 235–41.
   PubMed Web of Science ®Google Scholar
• Dong Z, Radinsky R, Fan D, et al. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 1994; 86: 913–20.
   PubMed Web of Science ®Google Scholar
• van de Vrie W, Gheuens EEO, Durante NMC, et al. In vitro and in vivo chemo-sensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour. J Cancer Res Clin Oncol 1993; 119: 609–14.
   Google Scholar
• Iwahashi T, Okochi E, Ariyoshi K, et al. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res 1993; 53: 5475–82.
   PubMed Web of Science ®Google Scholar
• Niwa K, Yamada K, Furukawa T, et al. Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate on reversing in vivo resistance of tumor cells to Adriamycin. Cancer Res 1992; 52: 3655–60.
   PubMed Web of Science ®Google Scholar
• Hitselberger Kanitz MH, Mastro JM, Moore RE, et al. In vivo expression of P-glycoprotein in a human colon carcinoma xenograft is modulated by therapy with free and monoclonal antibody-conjugated vinca alkaloids. Anticancer Res 1994; 14: 857–68.
   Google Scholar
• Berlion M, Arvelo F, Leonce S, et al. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft. In Vivo 1993; 7: 399–405.
   Google Scholar
• Ferrandis E, Da Silva J, Riou G, et al. Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse. Cancer Res 1994; 54: 2256–61.
   Web of Science ®Google Scholar
• Gheuens E, Van der Heyden S, Elst H, et al. Multidrug resistance in rat colon carcinoma cell lines CC531, CC531mdr+ and CC531rev. Jpn J Cancer Res 1993; 84: 1201–8.
   Google Scholar
• Johnson RK, Chitnis MP, Embrey WM, et al. In vivo characteristics of resistance and cross-resistance of an Adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 1978; 62: 1535–47.
   PubMedGoogle Scholar
• Shinoda H, Inaba M Tsuruo T. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52. Cancer Res 1989; 49: 1722–6.
   PubMed Web of Science ®Google Scholar
• Radel S, Fredericks W, Mayhew E, et al. P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells. Cancer Chemother Pharmacol 1990; 25: 241–6.
   PubMedGoogle Scholar
• Boesch D, Gavériaux C, Jachez B, et al. In vivo circumvention of P-glycopro-tein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51: 4226–33.
   PubMed Web of Science ®Google Scholar
• Sato W, Fukazawa N, Suzuki T, et al. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res 1991; 51: 2420–4.
   PubMed Web of Science ®Google Scholar
• Kühl JS, Sikic BI, Blume KG, et al. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. Exp Hematol 1992; 20: 1048–54.
   Google Scholar
• Shinoda H, Ebisu H, Mitsuhashi J, et al. Therapeutic efficacy of combination of antitumor agent with AHC-52 against multidrug-resistant cells in the intravenously inoculated P388 leukemia model. Cancer Chemother Pharmacol 1992; 30: 355–40.
   Google Scholar
• Sato W, Fukazawa N, Nakanishi O, et al. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995; 35: 271–7.
   PubMed Web of Science ®Google Scholar
• Volm M, Bak M, Efferth T, et al. Induced multidrug resistance in murine leukemia L1210 and associated changes in a surface-membrane glycoprotein. J Cancer Res Clin Oncol 1989; 115: 17–24.
   PubMedGoogle Scholar
• Efferth T, Klett T, Mattern J, et al. Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo. <i>Antican-cer Res1991; 11: 1275–80.
   Google Scholar
• Wang L, Yang C-PH, Horwitz SB, et al. Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate. Cancer Chemother Pharmacol 1994; 34: 96–102.
   Google Scholar
• Watanabe T, Naito M, Kokubu N, et al. Regression of established tumors expressing P-glycoprotein by combinations of Adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J Natl Cancer Inst 1997; 89: 512–8.
   PubMed Web of Science ®Google Scholar
• Satta T, Isobe K-i, Yamauchi M, et al. Establishment of drug resistance in human gastric and colon carcinoma xenograft lines. Jpn J Cancer Res 1991; 82: 593–8.
   Google Scholar
• Mimnaugh EG, Fairchild CR, Fruehauf JP, et al. Biochemical and pharmacological characterization of MCF-7 drug-sensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice. Biochem Pharmacol 1991; 42: 391–402.
   Google Scholar
• Leveille-Webster CR, Arias IA. Establishment and serial quantification of intra-hepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance. Clin Cancer Res 1996; 2: 695–706.
   Google Scholar
• Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996; 56: 4171–9.
   PubMed Web of Science ®Google Scholar
• Broxterman HJ, Feller N, Kuiper CM, et al. Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumor xenografts. Int J Cancer 1995; 61: 880–6.
   Google Scholar
• Plumb JA, Wishart GC, Setanoians A, et al. Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. Biochem Pharmacol 1994; 47: 257–66.
   Google Scholar
• Zou Y, Ling YH, Van NT, et al. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res 1994; 54: 1479–84.
   PubMed Web of Science ®Google Scholar
• Scott AM, Rosa E, Mehta BM, et al. In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody. Nucl Med Biol 1995; 22: 497–504.
   PubMed Web of Science ®Google Scholar
• Hill AB, Beck WT, Trent JM. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line. Cancer Res 1988; 48: 393–8.
   Google Scholar
• Bellamy WT, Odeleye A, Finley P, et al. An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. Am J Pathol 1993; 142: 691–8.
   PubMed Web of Science ®Google Scholar
• Bellamy WT, Mendibles P, Bontje P, et al. Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant pheno-type. Cancer Chemother Pharmacol 1996; 37: 305–16.
   Google Scholar
• Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res 1996; 56: 4332–7.
   Google Scholar
• Colombo T, Gonzalez Paz O D’Incalci M. Distribution and activity of doxoru-bicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 1996; 73: 866–71.
   PubMed Web of Science ®Google Scholar
• Schecter RL, Woo A, Duong M, et al. In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model. Cancer Res 1991; 51: 1434–42.
   PubMed Web of Science ®Google Scholar
• Miyamoto K-I, Wakabayashi D, Minamino T, et al. Characterization of naturally acquired multiple drug resistance of Yoshida rat ascites hepatoma AH66 cell line. Anticancer Res 1996; 16: 1235–40.
   Google Scholar
• Yang J-M, Goldenberg S, Gottesmann MM, et al. Characteristics of P388/ VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res 1994; 54: 730–7.
   Google Scholar
• Yang J-M, Hait WN. Use of multidrug resistant L1210 cell line for in vitro and in vivo drug screening. Proc Am Assoc Cancer Res 1991; 32: 364.
   Google Scholar
• Keller RP, Altermatt HJ, Nooter K, et al. SDZ PSC 833, a non-immunosuppres-sive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992; 50: 593–7.
   PubMed Web of Science ®Google Scholar
• Christensen JG, LeBlanc GA. Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res 1996; 56: 574–81.
   PubMed Web of Science ®Google Scholar
• Pearson JW, Fogler WE, Volker K, et al. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991; 83: 1386–91.
   PubMed Web of Science ®Google Scholar
• Leonessa F, Green D, Licht T, et al. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br J Cancer 1996; 73: 154–61.
   PubMed Web of Science ®Google Scholar
• Jansen WJM, Pinedo HM, Kuiper CM, et al. Biochemical modulation of ‘classical’ multidrug resistance by BIBW22BS, a potent derivative of dipyridamole. Ann Oncol 1994; 5: 733–9.
   PubMed Web of Science ®Google Scholar
• O’Conner R, Liu C, Ferris CA, et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 1995; 86: 4286–94.
   Google Scholar
• Liu C, Lambert JM, Teicher BA, et al. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemother-apeutic drugs. Blood 1996; 87: 3892–8.
   PubMed Web of Science ®Google Scholar
• Boven E, Winograd B, Berger DP, et al. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 1992; 52: 5940–7.
   Google Scholar
• Biedler JL, Riehm H, Peterson RHF, et al. Membrane-mediated drug resistance and phenotypic reversion to normal growth behavior of Chinese hamster cells. J Natl Cancer Inst 1975; 55: 671–80.
   Google Scholar
• Scotlandi K, Serra M, Nicoletti G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 1996; 56: 2434–9.
   PubMed Web of Science ®Google Scholar
• Serra M, Scotlandi K, Manara MC, et al. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 1993; 13: 323–30.
   PubMed Web of Science ®Google Scholar
• Bashir I, Sikora K, Abel P, et al. Establishment and in vivo characterization of multidrug-resistant Dunning R3327 rat prostate-carcinoma cell-lines. Int J Cancer 1994; 57: 719–26.
   PubMedGoogle Scholar
• Fichtner I, Stein U, Hoffmann J, et al. Characterization of four drug-resistant P388 sublines: resistance/sensivity in vivo, resistance- and proliferation-markers, immu-nogenicity. Anticancer Res 1994; 14: 1995–2004.
   Google Scholar
• Killion JJ, Radinsky R, Dong Z, et al. The immunogenic properties of drug-resistant murine tumor cells do not correlate with expression of the MDR pheno-type. Cancer Immunol Immunother 1993; 36: 381–6.
   Google Scholar
• Formelli F, Rossi C, Supino R, et al. In vivo characterization of a doxorubicin resistant B16 melanoma cell line. Br J Cancer 1986; 54: 223–33.
   Google Scholar
• Ganapathi R, Grabowski D, Schmidt H, et al. Characterization in vitro and in vivo of progressively Adriamycin-resistant B16-BL6 mouse melanoma cells. Cancer Res 1987; 47: 3464–8.
   PubMed Web of Science ®Google Scholar
• Bradley G, Sharma R, Rajalakshmi S, et al. P-Glycoprotein expression during tumor progression in the rat liver. Cancer Res 1992; 52: 5154–61.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Mickisch GH, Pastan I. In vivo models of P-glycoprotein-mediated multidrug resistance. Cancer Treat Res 1994; 73: 107–28.
   Google Scholar
• Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 42–9.
   Web of Science ®Google Scholar
• Mattern J, Bak M, Hahn EW, et al. Human tumor xenografts as model for drug testing. Cancer Metas Rev 1988; 7: 263–84.
   Google Scholar
• Fidler IJ. Role of the organ environment in the pathogenesis of cancer metastasis. Proc Am Assoc Cancer Res 1993; 34: 570.
   Google Scholar
• Genne P, Dimanche-Boitrel MT, Mauvernay RY, et al. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Res 1992; 52: 2797–801.
   Google Scholar
• Mehta BM, Rosa E, Biedler JL, et al. In vivo uptake of carbon-14-colchicine for identification of tumor multidrug resistance. J Nucl Med 1994; 35: 1179–84.
   PubMed Web of Science ®Google Scholar
• Ballinger JR, Hua HA, Berry BW, et al. 99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995; 16: 253–7.
   PubMed Web of Science ®Google Scholar
• Galski H, Sullivan M, Willingham MC, et al. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia. Mol Cell Biol 1989; 9: 4357–63.
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Merlino GT, Galski H, et al. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991; 88: 547–51.
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Licht T, Merlino GT, et al. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res 1991; 51: 5417–24.
   PubMed Web of Science ®Google Scholar
• Levêque D, Jehl F. P-Glycoprotein and pharmacokinetics. Anticancer Res 1995; 15: 331–6.
   PubMed Web of Science ®Google Scholar
• Fischer GA, Lum BL, Hausdorff J, et al. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996; 32A: 1082–8.
   Google Scholar
• Horton JK, Thimmaiah KN, Houghton JA, et al. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xeno-grafts. Biochem Pharmacol 1989; 38: 1727–36.
   PubMed Web of Science ®Google Scholar
• Hyafil F, Vergely C, Du Vignaud P, et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595–602.
   PubMed Web of Science ®Google Scholar
• Colombo T, Zucchetti M D’Incalci M. Cyclosporin A markedly changes the distribution of doxorubincin in mice and rats. J Pharmacol Exp Ther 1994; 269: 22–7.
   PubMed Web of Science ®Google Scholar
• Gonzalez O, Colombo T, De Fusco M, et al. Changes in doxorubicin distribution and toxocity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol 1995; 36: 335–40.
   PubMed Web of Science ®Google Scholar
• Arvelo F, Poupon MF, Bichat F, et al. Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts. Eur J Cancer 1995; 31A: 1862–8.
   PubMedGoogle Scholar
• Keller RP, Altermatt HJ, Donatsch P, et al. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 1992; 51: 433–8.
   PubMed Web of Science ®Google Scholar
• Desrayaud S, Guntz P, Scherrmann J-M, et al. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci 1997; 61: 153–63.
   PubMed Web of Science ®Google Scholar
• van Asperen J, Schinkel AH, Beijnen JH, et al. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 1996; 88: 994–9.
   PubMed Web of Science ®Google Scholar
• Leu B-L, Huang J-d. Inhibition of intestinal P-glycoprotein and effects on etopo-side absorption. Cancer Chemother Pharmacol 1995; 35: 432–6.
   PubMed Web of Science ®Google Scholar
• Speeg KV, Maldonado AL, Liaci J, et al. Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology 1992; 15: 899–903.
   PubMed Web of Science ®Google Scholar
• Ellis AG, Crinis NA Webster LK. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 1996; 38: 81–7.
   PubMed Web of Science ®Google Scholar
• Genne P, Duchamp O, Solary E, et al. Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anti-Cancer Drug Design 1995; 10: 103–18.
   Google Scholar
• Genne P, Coudert B, Pelletier H, et al. Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance. Anticancer Res 1989; 9: 1655–60.
   PubMed Web of Science ®Google Scholar
• Lemaire M, Bruelisauer A, Guntz P, et al. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol 1996; 38: 481–6.
   PubMed Web of Science ®Google Scholar
• Relling MV. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 1996; 18: 350–6.
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967–72.
   PubMed Web of Science ®Google Scholar
• Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155–99.
   PubMed Web of Science ®Google Scholar
• Ford JM. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers. Eur J Cancer 1996; 32A: 991–1001.
   PubMed Web of Science ®Google Scholar
• Pennock GD, Dalton WS, Roeske WR, et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991; 83: 105–10.
   PubMed Web of Science ®Google Scholar
• Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 1983; 67: 889–94.
   PubMedGoogle Scholar
• Cros S, Guilbaud N, Berlion M, et al. In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model. Cancer Chemother Pharmacol 1992; 30: 491–4.
   PubMed Web of Science ®Google Scholar
• Loor F, Boesch D, Gavériaux C, et al. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-medi-ated tumour cell multidrug resistance. Br J Cancer 1992; 65: 11–8.
   Google Scholar
• Watanabe T, Naito M, Oh-hara T, et al. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models. Jpn J Cancer Res 1996; 87: 184–93.
   PubMedGoogle Scholar
• Bright JM, Buss DD. Effects of verapamil on chronic doxorubicin-induced cardio-toxicity in dogs. J Natl Cancer Inst 1990; 82: 963–4.
   Google Scholar
• Sridhar R, Dwivedi C, Anderson J, et al. Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst 1992; 84: 1653–60.
   PubMed Web of Science ®Google Scholar
• van de Vrie W, Jonker AM, Marquet RL, et al. The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat. J Cancer Res Clin Oncol 1994; 120: 533–8.
   Google Scholar
• Froidevaux S, Loor F. Myeloid and lymphoid cell alterations in normal mice exposed to chemotherapy with doxorubicin and/or the multidrug-resistance reversing agent SDZ PSC 833. Int J Cancer 1994; 59: 133–40.
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Yusa K, Sudo Y, et al. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Cancer Res 1989; 49: 5537–42.
   PubMed Web of Science ®Google Scholar
• Ohkawa K, Hatano T, Yamada K, et al. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res 1993; 53: 4238–42.
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Rahman A, Pastan I, et al. Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. J Natl Cancer Inst 1992; 84: 804–5.
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Hamada H, Sato S, et al. Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn J Cancer Res 1989; 80: 627–31.
   PubMedGoogle Scholar
• Rittmann-Grauer LS, Yong MA, Sanders V, et al. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 1992; 52: 1810–6.
   Google Scholar
• Mickisch GH, Pai LH, Gottesman MM, et al. Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice. Cancer Res 1992; 52: 4427–32.
   PubMed Web of Science ®Google Scholar
• Fogler WE, Pearson JW, Volker K, et al. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J Natl Cancer Inst 1995; 87: 94–104.
   Google Scholar
• Hamada H, Tsuruo T. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986; 83: 7785–9.
   PubMed Web of Science ®Google Scholar
• Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA. 1992; 89: 5824–8.
   PubMed Web of Science ®Google Scholar
• Meyers MB, Rittmann-Grauer L, O’Brien JP, et al. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells. Cancer Res 1989; 49: 3209–14.
   PubMed Web of Science ®Google Scholar
• Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99–103.
   PubMed Web of Science ®Google Scholar
• Podda S, Ward M, Himelstein A, et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992; 89: 9676–80.
   PubMed Web of Science ®Google Scholar
• Baudard M, Pastan I Gottesman MM. Transfer of the MDR1 gene into haematopoietic cells. Eur J Cancer 1996; 32A: 1019–23.
   Google Scholar
• Bellamy WT. Prediction of response to drug therapy of cancer. Drugs 1992; 44: 690–708.
   PubMed Web of Science ®Google Scholar
• Weisenthal LM. Antineoplastic drug screening belongs in the laboratory, not in the clinic. J Natl Cancer Inst 1992; 84: 466–9.
   Google Scholar
• Martin DS, Balis ME, Fisher B, et al. Role of murine tumor models in cancer treatment research. Cancer Res 1986; 46: 2189–92.
   PubMed Web of Science ®Google Scholar
• van der Heyden S, Gheuens E, van de Vrie W, et al. 5¢-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related to P-gp 170 expression. Jpn J Cancer Res 1994; 85: 13–6.
   Google Scholar
• Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug-resis-tant multiple myeloma by cyclosporin. Lancet 1992; 340: 255–9.
   PubMed Web of Science ®Google Scholar
• List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652–60.
   PubMed Web of Science ®Google Scholar
• Verweij J, Herweijer H, Oosterom R, et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 1991; 64: 361–4.
   PubMed Web of Science ®Google Scholar
• Rodenburg CJ, Nooter K, Herweijer H, et al. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 1991; 2: 305–6.
   PubMed Web of Science ®Google Scholar
• Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995; 9: 363–82.
   PubMed Web of Science ®Google Scholar
• Ferry DR, Traunecker H Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996; 32A: 1070–81.
   PubMed Web of Science ®Google Scholar
• Sonneveld P. Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Eur J Cancer 1996; 32A: 1062–9.
   Google Scholar
• Volm M, Bak M, Efferth T, et al. Induced multidrug-resistance in murine sarcoma 180 cells grown in vitro and in vivo and associated changes in expression of multidrug-resistance DNA-sequences and membrane glycoproteins. Anticancer Res 1988; 8: 1169–78.
   PubMed Web of Science ®Google Scholar
• Slater LM, Sweet P, Stupecky M, et al. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 1986; 54: 235–8.
   PubMed Web of Science ®Google Scholar
• Formelli F, Cleris L Carsana R. Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. Cancer Chemother Pharmacol 1988; 21: 329–36.
   Google Scholar
• Capranico G, De Isabella P, Castelli C, et al. P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines. Br J Cancer 1989; 59: 682–5.
   Google Scholar
• Chauffert B, Martin M, Hammann A, et al. Amiodarone-induced enhancement of doxorubicin and 4¢-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res 1986; 46: 825–30.
   Google Scholar
• Mattern J, Bak M Volm M. Intrinsic and acquired multidrug resistance in human lung carcinomas grown in nude mice. Anticancer Res 1990; 10: 177–80.
   Google Scholar